Japanese Patent Office to grant patent for cancer vaccine technology

Regeneus (ASX: RGS), today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.

The Japanese Patent Office has issued a decision to allow a patent covering the company’s cancer vaccine technology for the treatment of cancer in humans and animals to be granted. The patent to be granted on Japanese Patent Application No. 2015-549902 entitled “Vaccines for the treatment or prevention of cancer and compositions for enhancing vaccine efficacy” will provide commercial rights in Japan through to 2033. A corresponding patent has been granted in Australia and corresponding patents are being pursued for grant in other key territories including the USA and Europe.

Read the full announcement on the ASX here.